The surge in MRNA stock comes after some SEC filings show that company insiders bought shares worth $6 million.

BioNTech (NASDAQ:BNTX – Get Free Report) will likely be issuing its quarterly earnings data before the market opens on Monday, March 10th. Analysts expect the company to announce earnings of $0.38 per ...

In a report released yesterday, Harry Gillis from Berenberg Bank maintained a Buy rating on BioNTech SE (BNTX – Research Report), with a price ...

We recently published a list of 10 Best Immunology Stocks To Buy Now. In this article, we are going to take a look at where ...

German biotech major BioNTech (Nasdaq: BNTX) has suffered a blow as it seeks to add new revenue streams beyond its COVID-19 ...

Moderna (MRNA) stock is climbing 8% after the drug maker won a key court case and its CEO bought shares on the open market.

Ugur Sahin, the co-founder and CEO of BioNTech SE (BNTX), sold $119.58 million worth of the Germany-based biotechnology ...

The US Patent Trial and Appeal Board handed a massive victory to Pfizer (NYSE: PFE) and BioNTech (Nasdaq: BNTX) on Wednesday, ...

BioNTech's malaria vaccine trial faces an FDA clinical hold. The company is addressing concerns and collaborating with ...

A German court on Wednesday ruled that Pfizer and its partner BioNTech violated a COVID-19 vaccine patent held by Moderna. In ...

In this article, we are going to take a look at where BioNTech SE (NASDAQ:BNTX) stands against other best immunology stocks to buy now. Immunology is a rapidly advancing field with significant ...

The court said Pfizer and BioNTech would have to provide information on earnings derived from the use of the patent and that ...